Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 10Wound Infection 1Urologic Diseases 1Urinary Tract Infections 1Urinary Bladder Diseases 1Ureteral Neoplasms 1Recurrence 1Neoplasms 1Muscle Invasive Bladder Cancer 1Infections 1Disease Progression 1Cross Infection 1Carcinoma, Transitional Cell 1Bacterial Infections 1

Interventions

pembrolizumab 21enfortumab vedotin 13Gemcitabine 12Nivolumab 8Cisplatin 8Carboplatin 8Magnetic Resonance Spectroscopy 6Specimen Handling 5Docetaxel 5toripalimab 4sacituzumab govitecan 4Paclitaxel 4Ipilimumab 4atezolizumab 3Mitomycin 3Fluorouracil 3disitamab vedotin 2cabozantinib 2avelumab 2Radiosurgery 2Platinum 2Injections 2Immunotherapy 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Biopsy 2zanidatamab 1tremelimumab 1tamibarotene 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Transitional Cell × Cystectomy × Clear all
NCT06184516 2025-09-15

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

University of Florida

Phase 2 Recruiting
147 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡